2020-12-02
Camurus AB today announced that Camurus licensee Braeburn has received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) regarding its new drug application (NDA) for Brixadi.
Read the full press release: https://www.camurus.com/
2020-04-03
Camurus announced today continued strong revenue growth driven by increasing demand for weekly and monthly Buvidal®…
Read more2020-02-14
Camurus has published their Full year report 2019
Read more2019-12-13
The directed share issue (which was completed on December 6, 2019) of approximately 3,7 million shares will raise pr…
Read more2019-12-13
The directed share issue (which was completed on December 6, 2019) of approximately 3,7 million shares will raise pr…
Read more2019-11-04
GRANULDISK has launched biodegradable granules, which eliminate the need for pre-washing, all while being kind to th…
Read more